Chakma Justin 4
4 · ARS Pharmaceuticals, Inc. · Filed Dec 12, 2024
Insider Transaction Report
Form 4
Chakma Justin
Chief Business Officer
Transactions
- Exercise/Conversion
Common Stock
2024-12-10$0.84/sh+50,000$42,000→ 186,380 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-12-10−50,000→ 0 totalExercise: $0.84Exp: 2029-07-04→ Common Stock (50,000 underlying) - Sale
Common Stock
2024-12-10$13.15/sh−50,000$657,625→ 136,380 total
Footnotes (2)
- [F1]The weighted average sale price for the transaction reported was $13.1525, and the range of prices were between $12.95 and $13.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- [F2]Immediately exercisable.